نتایج جستجو برای: interferon beta 1b
تعداد نتایج: 269096 فیلتر نتایج به سال:
Eleven male patients with genital warts were given injections of fibroblast interferon (300 u) and placebo into the bases of two similar warts. The changes in size of the treated warts compared with that of the controls suggested that interferon did inhibit the growth of the warts. The dose given was probably insufficient for a dramatic effect. In one patient, however, a wart on the penile shaf...
5. Monoclonal Anti body Multi ple sclerosis (MS) is a complex immunopathologic disorder of the central nervous system (CNS). For the past several years, there have been six agents approved by regulatory agencies to treat relapsing forms of multi ple sclerosis (MS): interferon beta-1b, intramuscular interferon beta-1a, subcutaneous interferon beta-1a, glati ramer acetate, natalizumab, and mitoxa...
The anti-inflammatory potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, as reflected by modulation of C-reactive protein (CRP), might be beneficial in the treatment of patients with multiple sclerosis (MS). We evaluated serum levels of high-sensitivity (hs)-CRP in relapsing-remitting MS patients receiving interferon-beta 1b and atorvastatin as add-on therapy. This study s...
BACKGROUND Interferon beta-la and -1b have been increasingly used for the treatment of multiple sclerosis (MS). The most frequent systemic adverse effects are flu-like symptoms. Laboratory abnormalities include asymptomatic leukopenia and elevated hepatic transaminases. Myelodysplastic Syndrome (MDS) refers to a spectrum of hematological disorders which can occur in different situations. Severa...
Recombinant interferon-beta-1b (IFN-beta-1b) is used clinically in the treatment of multiple sclerosis. In common with many biological ligands, IFN-beta-1b exhibits a relatively short serum half-life, and bioavailability may be further diminished by neutralizing antibodies. While PEGylation is an approach commonly employed to increase the blood residency time of protein therapeutics, there is a...
The review by Goodin and Bates in this issue 1 on treating multiple sclerosis (MS) when it might first be heralding is indeed timely for a number of reasons. First, virtually all of the first line current disease modifying drugs (interferon beta and glatiramer acetate) have now been shown to be effective at the stage called 'CIS' or the first 'clinically isolated syndrome' in reducing the chanc...
Background: It has been reported that liver function alterations occur in 8–38% of patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta in controlled clinical trials or in prospective but non-controlled studies. We report herein a case of symptomatic liver dysfunction associated with two-year-period of regular interferon-beta-1a (Avonex®) intramuscular inje...
OBJECTIVE To evaluate the cost utility of interferon beta-1b in secondary progressive multiple sclerosis. DESIGN Population based cost utility model (healthcare perspective). Data on use of health services were obtained from case records and routine morbidity data and utility values from a EuroQol survey. Local and published costs were used. Effectiveness was modelled using data on relative r...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید